Fennec Pharmaceuticals Inc.
FENC
$6.01
-$0.27-4.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 123.69% | 278.09% | 647.88% | 1,299.50% | 1,284.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 123.69% | 278.09% | 647.88% | 1,299.50% | 1,284.50% |
| Cost of Revenue | 152.90% | 384.85% | 560.79% | 846.96% | 1,363.95% |
| Gross Profit | 121.85% | 272.40% | 652.50% | 1,326.53% | 1,279.78% |
| SG&A Expenses | 26.82% | 50.57% | 39.17% | 46.32% | 59.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.18% | 58.14% | 41.02% | 40.64% | 41.03% |
| Operating Income | 120.11% | 109.85% | 124.48% | 125.67% | 43.46% |
| Income Before Tax | 99.56% | 94.40% | 110.34% | 110.91% | 32.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 97.28% | 94.40% | 110.34% | 110.91% | 32.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.28% | 94.40% | 110.34% | 110.91% | 32.34% |
| EBIT | 120.11% | 109.85% | 124.48% | 125.67% | 43.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 98.26% | 94.97% | 110.12% | 109.99% | 33.09% |
| Normalized Basic EPS | 100.96% | 94.98% | 110.23% | 110.10% | 32.73% |
| EPS Diluted | 86.15% | 86.50% | 103.62% | 103.01% | 32.41% |
| Normalized Diluted EPS | 90.70% | 86.81% | 104.02% | 103.82% | 32.73% |
| Average Basic Shares Outstanding | 2.56% | 2.02% | 1.76% | 1.35% | 1.41% |
| Average Diluted Shares Outstanding | 6.36% | 5.82% | 5.58% | 5.19% | 1.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |